The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are used to treat patients with non‐small cell lung cancer (NSCLC) and EGFR driver mutations. Although some patients discontinued these treatments because of adverse events, it is unclear whether switching EGFR‐TKI b...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Asia Pac J Clin Oncol
Main Authors: Sakata, Yoshihiko, Kawamura, Kodai, Shingu, Naoki, Hiroshige, Shigeo, Yasuda, Yuko, Eguchi, Yoshitomo, Anan, Keisuke, Hisanaga, Junpei, Nitawaki, Tatsuya, Nakano, Aiko, Ichikado, Kazuya
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7379949/
https://ncbi.nlm.nih.gov/pubmed/30506897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13103
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares